cagrilintide and semaglutide 2.4 mg The next frontier in metabolic health: Cagrilintide-Semaglutide the evolving landscape of therapies Cagrilintide + Semaglutide — Factor

Mechanism of Action Tirzepatide: Dual incretin (GIP + GLP-1) enhanced metabolic impact Wegovy: GLP-1 receptor agonist now with higher receptor engagement Weight Loss Outcomes Tirzepatide: ~22% weight reduction in trials Wegovy 7.2 mg: ~2021% weight reduction The efficacy gap is narrowing significantly Cardiometabolic Profile Wegovy: Strong, established cardiovascular outcome data Tirzepatide: Superior glycemic control and insulin sensitivity Safety & Tolerability Both therapies show dose-dependent GI side effects Overall safety profiles remain comparable The Big Picture We are witnessing a shift from: Single-hormone optimization (high-dose semaglutide) to Multi-hormone targeting (tirzepatide) Conclusion While Wegovy is rapidly closing the efficacy gap with dose escalation, Tirzepatide continues to lead as a next-generation metabolic therapy

(December 2005)

The price: around $300 a month

The FDA has been cracking down on peptide compounding, but political pressure may shift enforcement in coming years